



Stephan Harbarth

Contact

Stephan Harbarth

Publications (14)

Grant R, van Linde M, Buetti N, Jackson H, Abbas M, Sobel J, Sommerstein R, Eder M, Balmelli C, Troillet N, Schreiber P, Jent P, Senn L, Flury D, Tschudin-Sutter S, Buettcher M, Süveges M, Urbini L, Keiser O, Roder U, Harbarth S, Zanella M, CH-SUR study group. In-hospital outcomes of healthcare-associated COVID-19 (Omicron) versus healthcare-associated influenza: a retrospective, nationwide cohort study in Switzerland. *Clin Infect Dis* 2024

Martischang R, Seth-Smith H, Verschuuren T, Héquet D, Gaïa N, François P, Fluit A, Earnshaw J, Seiffert S, Tacconelli E, Cherkaoui A, Harbarth S, Egli A, Kohler P. Regional spread of an atypical ESBL-producing ST131H89 clone among different human and environmental reservoirs in Western Switzerland. *Antimicrob Agents Chemother* 2024:e0092523.

Sommerstein R, Troillet N, Harbarth S, van Linde M, Vuichard-Gysin D, Kuster S, Widmer A, Swissnoso group. Timing of Cefuroxime Surgical Antimicrobial Prophylaxis and Its Association With Surgical Site Infections. *JAMA Netw Open* 2023; 6:e2317370.

Bellini C, Eder M, Senn L, Sommerstein R, Vuichard-Gysin D, Schmiedel Y, Schlegel M, Harbarth S, Troillet N. Providing care to patients in contact isolation: is the systematic use of gloves still indicated?. *Swiss Med Wkly* 2022; 152:w30110.

Vuichard-Gysin D, Sommerstein R, Kronenberg A, Buetti N, Eder M, Piezzi V, Gardiol C, Schlegel M, Harbarth S, Widmer A. High adherence to national IPC guidelines as key to sustainable VRE control in Swiss hospitals: a cross-sectional survey. *Antimicrob Resist Infect Control* 2022; 11:19.

Fröhlich G, van Linde M, Abbas M, Keiser O, Thiabaud A, Roelens M, Cusini A, Flury D, Schreiber P, Buettcher M, Corti N, Vuichard-Gysin D, Troillet N, Sauser J, Gaudenz R, Damonti L, Balmelli C, Iten A, Widmer A, Harbarth S, Sommerstein R. Hospital outcomes of community-acquired COVID-19 versus influenza: Insights from the Swiss hospital-based surveillance of influenza and COVID-19. *Euro Surveill* 2022; 27

Kohler P, Egli A, Petignat C, Schlegel M, Münzer T, Harbarth S, Gardiol C, Babouee Flury B, Albrich W, Seth-Smith H, Nolte O, Qalla Widmer L, Lemmenmeier E, Rettenmund G, Kessler S, Seiffert S, Héquet D. Molecular Epidemiology and Risk Factors for Extended-Spectrum β -Lactamase-Producing Enterobacterales in Long-Term Care Residents. *J Am Med Dir Assoc* 2021

Metsini A, Sommerstein R, Harbarth S, Marschall J, Schlegel M, Maag J, Eder M, Vuichard-Gysin D, Gardiol C, Zingg W, Widmer A, The Swissnoso Network. Evaluation of existing and desired measures to monitor, prevent and control healthcare-associated infections in Swiss hospitals. *Swiss Med Wkly* 2021; 151:w20516.

von Dach E, Bochud P, Kaiser L, Harbarth S, Rossel A, McCallin S, Lemmenmeier E, Kohler P, Huttner B, Gayet-Ageron A, Flury D, Cuvelier C, Prendki V, Brunel A, Albrich W, Huttner A. Effect of C-Reactive Protein-Guided Antibiotic Treatment Duration, 7-Day Treatment, or 14-Day Treatment on 30-Day Clinical Failure Rate in Patients With Uncomplicated Gram-Negative Bacteremia: A Randomized Clinical Trial. *JAMA* 2020; 323:2160-2169.

Kohler P, Schlegel M, Petignat C, Kuster S, Kahlert C, Héquet D, Harbarth S, Balmelli C, Egli A, Albrich W, Fulchini R, Kronenberg A. Antibiotic resistance in Swiss nursing homes: analysis of National Surveillance Data over an 11-year period between 2007 and 2017. *Antimicrob Resist Infect Control* 2018; 7:88.

Huttner A, Albrich W, Bochud P, Gayet-Ageron A, Rossel A, Dach E, Harbarth S, Kaiser L. PIRATE project: point-of-care, informatics-based randomised controlled trial for decreasing overuse of antibiotic therapy in Gram-negative bacteraemia. *BMJ Open* 2017; 7:e017996.

Huttner A, Bernasconi E, Viereck V, Kavvadias T, Kling K, Ryu G, Hülder T, Gröger S, Scheiner D, Alaimo C, Harbarth S, Poolman J, Kuhn A, de Vallière S, Hatz C, van den Dobbelen G, Abbanat D, Hornacek A, Frölich R, Dreyer A, Martin P, Davies T, Fae K, van den Nieuwenhof I, Thoelen S, Fonck V. Safety, immunogenicity, and preliminary clinical efficacy of a vaccine against extraintestinal pathogenic *Escherichia coli* in women with a history of recurrent urinary tract infection: a randomised, single-blind, placebo-controlled phase 1b trial. *Lancet Infect Dis* 2017; 17:528–537.

Olearo F, Albrich W, Vernaz N, Harbarth S, Kronenberg A. *Staphylococcus aureus* and methicillin resistance in Switzerland: regional differences and trends from 2004 to 2014. *Swiss Med Wkly* 2016; 146:w14339.

Albrich W, Harbarth S. Pros and cons of using biomarkers versus clinical decisions in start and stop decisions for antibiotics in the critical care setting. *Intensive Care Med* 2015

Projects (0)

No results found.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch